Sacubitril/Valsartan Under Review for Heart Failure With Preserved Ejection Fraction
Renal & Urology News,
The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for sacubitril/valsar…
Sacubitril/Valsartan Under Review for Heart Failure With Preserved Ejection Fraction
MPR,
The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for sacubitril/valsar…
Sacubitiril/Valsartan Combination Shows Reduction in Hospitalizations in Women with Diastolic Heart Failure
Pharmacy Times,
Certain subgroups may see a greater reduction in heart failure (HF) hospitalizations and cardiovascular death with the…
Insufficienza cardiaca a frazione di eiezione preservata: sacubitril/valsartan efficace nelle donne e in pazienti pi gravi
Pharmastar Italy,
Al congresso americano di cardiologia dell'AHA sono stati presentate nuove analisi di sottogruppi dello studio PARAGON-HF…
Benefits of Sacubitril/Valsartan Appear to Be Greater in Certain HFpEF Subgroups
MPR,
Treatment with sacubitril/valsartan (Entresto; Novartis) was found to provide greater benefits in certain patients with heart…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Biospace,
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
USA Life Sciences Database,
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Jotup,
"Understanding the correlation between time since hospitalization and treatment benefit may help inform optimization of care…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
ProfitQuotes.com,
EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ -- Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
BioTech Gate,
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
PharmiWeb,
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Fox 40,
SOURCE Novartis Pharmaceuticals Corporation EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ -- Entresto (sacubitril/valsartan…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
WBOC 16,
SOURCE Novartis Pharmaceuticals Corporation EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ -- Entresto (sacubitril/valsartan…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Ariva,
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Ticker Tech,
EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ -- Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Morning Star,
PR Newswire EAST HANOVER, N.J., Nov. 17, 2019 EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ -- Entresto (sacubitril/valsartan…
Novartis PARAGON-HF Analyses Suggest Entresto® Benefit Beyond HFrEF
The Street,
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
Benzinga,
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…
Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
PR Newswire,
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF…